The goal of this observational study is to systematically assess the presence and distribution of CMR-defined inflammation and fibrosis in clinically stable HT recipients with DSA detected during active screening for AMR surveillance. The main outcome is to study the prevalence of fibrosis, edema and of altered T1 mapping values in patients with DSA and the prevalence of patients with DSA among all the enrolled patients
Age > 18 years
Post heart transplantation follow-up between 1 and 15 y
Ambulatory clinical stable
Left ventricular ejection fraction (LVEF) > 40% (as assessed by complete cardiac ultrasound within 3 months before the enrolment)
Unplanned hospitalization for cardiovascular causes in the previous three months
Biopsy-proven cellular (2R or greater) or AMR (pAMR> 1 ) in the previous 3 months
Any contraindication to CMR
Known pregnancy
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lead sponsor
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
Collaborator
Azienda Ospedaliera dei Colli
Collaborator
ASST Grande Ospedale Metropolitano Niguarda
Collaborator